BLUF:
* To determine whether AI is ‘improving exponentially’, ‘hitting the wall’, or any other claim which involves a quantity or magnitude (e.g. ‘This model was a big leap/small increment’). We need a good y-axis: an interval scale of AI capability which means +1 unit always represents the same degree of ‘how much better’, in the same way +1 degree Celsius is always the same amount of ‘how much hotter’.
* Yet there is no good y-axis for AI capability. All our...
Summary
* The animal welfare movement has already seen an influx in funding and should prepare for the possibility of more.
* The EA Animal Welfare Fund is encouraging those working in animal advocacy to actively set aside time and resources now to concretely plan for scaling sustainably, and we’ll support you in doing that.
* We’re requesting advocates set concrete ambitious goals and submit plans t...
Public service announcement
1. Applications are now open for our first ever round of the Charity Entrepreneurship Incubation Program dedicated exclusively to animal welfare. Learn more about what’s different this round here and apply...
New anti-malaria treatment clears phase 3 trials.
I just found that there is a new anti-malarial alternative to artemisinin, the most common antimalarial chemical, which has successfully completed Phase 3 trials. Its nickname is GanLum and apparently has quite powerful effects:
This is an important advance because resistance to artemisinin is one of the growing concerns in the fight against malaria.
You may read more in https://www.npr.org/sections/goats-and-soda/2025/11/12/g-s1-97487/malaria-drug-new and https://www.mmv.org/newsroom/news-resources-search/phase-3-trial-next-generation-malaria-treatment-ganaplacide-lumefantrine .
Very interesting! And very hopeful! Thanks for sharing!